0001001316 2009-10-01 2009-10-31 0001001316 2009-12-31 0001001316 us-gaap:ConvertibleNotesPayableMember 2010-03-08 0001001316 tgtx:IconClinicalResearchMember 2010-03-08 0001001316 us-gaap:ConvertibleNotesPayableMember 2010-03-01 2010-03-08 0001001316 tgtx:IconClinicalResearchMember 2010-03-01 2010-03-08 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember 2010-01-01 2010-12-31 0001001316 2010-12-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember 2010-12-31 0001001316 us-gaap:SeriesAPreferredStockMember 2010-12-31 0001001316 us-gaap:CommonStockMember 2010-12-31 0001001316 tgtx:IconClinicalResearchMember 2011-03-31 0001001316 tgtx:BeforeAmendmentMember tgtx:IconClinicalResearchMember 2011-03-31 0001001316 tgtx:AfterAmendmentMember tgtx:IconClinicalResearchMember 2011-03-31 0001001316 2011-04-19 0001001316 2011-10-27 0001001316 2011-11-01 0001001316 2011-12-29 0001001316 tgtx:IconAndSwissPharmaMember 2011-12-29 0001001316 tgtx:ExcludingIconAndSwissPharmaMember 2011-12-29 0001001316 us-gaap:SeriesAPreferredStockMember tgtx:MrWeissMember 2011-12-29 0001001316 us-gaap:SeriesAPreferredStockMember tgtx:MrPowerMember 2011-12-29 0001001316 tgtx:TgBioMember 2011-12-29 0001001316 2011-11-29 2011-12-29 0001001316 us-gaap:SeriesAPreferredStockMember tgtx:MrWeissMember 2011-11-29 2011-12-29 0001001316 us-gaap:SeriesAPreferredStockMember tgtx:MrPowerMember 2011-11-29 2011-12-29 0001001316 2011-12-30 0001001316 2011-12-01 2011-12-30 0001001316 tgtx:TwoThousandTwelveIssuanceMember 2011-12-01 2011-12-30 0001001316 us-gaap:PrivatePlacementMember tgtx:TwoThousandTwelveIssuanceMember 2011-12-01 2011-12-30 0001001316 2011-01-01 2011-12-31 0001001316 us-gaap:SeriesAPreferredStockMember 2011-01-01 2011-12-31 0001001316 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001001316 tgtx:ThorntonRossLtdMember 2011-01-01 2011-12-31 0001001316 tgtx:NonControllingInterestInSubsidiaryMember 2011-01-01 2011-12-31 0001001316 tgtx:UsFederalIncomeTaxMember 2011-01-01 2011-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001001316 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0001001316 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-01-01 2011-12-31 0001001316 tgtx:LfbBiotechnologiesMember 2011-01-01 2011-12-31 0001001316 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001001316 us-gaap:ContingentlyIssuableSharesMember 2011-01-01 2011-12-31 0001001316 tgtx:LfbGroupMember 2011-01-01 2011-12-31 0001001316 2011-12-31 0001001316 tgtx:IconClinicalResearchMember 2011-12-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember 2011-12-31 0001001316 us-gaap:SeriesAPreferredStockMember 2011-12-31 0001001316 us-gaap:CommonStockMember 2011-12-31 0001001316 tgtx:NonControllingInterestInSubsidiaryMember 2011-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001001316 us-gaap:PreferredStockMember 2011-12-31 0001001316 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0001001316 us-gaap:CommonStockMember 2011-12-31 0001001316 us-gaap:ContingentlyIssuableSharesMember 2011-12-31 0001001316 tgtx:AristonMember 2011-12-31 0001001316 tgtx:IconConvertibleNotesMember 2011-12-31 0001001316 us-gaap:FairValueInputsLevel1Member 2011-12-31 0001001316 tgtx:NoninterestbearingMember 2011-12-31 0001001316 us-gaap:FairValueInputsLevel2Member 2011-12-31 0001001316 us-gaap:FairValueInputsLevel3Member 2011-12-31 0001001316 tgtx:ConvertibleNotesMember 2011-12-31 0001001316 tgtx:ExchangeForLicenseOptionMember 2011-12-31 0001001316 us-gaap:CommonStockMember 2011-12-31 0001001316 tgtx:BeforeCorrectionOfImmaterialErrorMember 2011-12-31 0001001316 tgtx:AfterCorrectionOfImmaterialErrorMember 2011-12-31 0001001316 2012-02-24 0001001316 2012-02-01 2012-02-24 0001001316 2012-04-30 0001001316 us-gaap:PreferredStockMember 2012-04-30 0001001316 us-gaap:RestrictedStockMember 2012-05-17 0001001316 2012-06-30 0001001316 tgtx:LfbBiotechnologiesMember 2012-11-09 0001001316 tgtx:LfbMember 2012-11-09 0001001316 tgtx:LfbBiotechnologiesMember 2012-11-01 2012-11-09 0001001316 tgtx:LfbMember 2012-11-01 2012-11-09 0001001316 2012-01-01 2012-12-31 0001001316 tgtx:IconClinicalResearchMember 2012-01-01 2012-12-31 0001001316 us-gaap:SeriesAPreferredStockMember 2012-01-01 2012-12-31 0001001316 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001001316 tgtx:NonControllingInterestInSubsidiaryMember 2012-01-01 2012-12-31 0001001316 tgtx:UsFederalIncomeTaxMember 2012-01-01 2012-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001001316 us-gaap:PreferredStockMember 2012-01-01 2012-12-31 0001001316 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-12-31 0001001316 tgtx:LfbBiotechnologiesMember 2012-01-01 2012-12-31 0001001316 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001001316 us-gaap:RestrictedStockMember 2012-01-01 2012-12-31 0001001316 tgtx:LfbGroupMember 2012-01-01 2012-12-31 0001001316 us-gaap:TreasuryStockMember 2012-01-01 2012-12-31 0001001316 tgtx:CollaborationAgreementMember 2012-01-01 2012-12-31 0001001316 tgtx:OpusMember 2012-01-01 2012-12-31 0001001316 tgtx:EquityPipe2011Member 2012-01-01 2012-12-31 0001001316 us-gaap:PreferredStockMember 2012-01-01 2012-12-31 0001001316 tgtx:PreferredRestrictedStockMember 2012-01-01 2012-12-31 0001001316 tgtx:CommonRestrictedStockMember 2012-01-01 2012-12-31 0001001316 us-gaap:SeriesAPreferredStockMember tgtx:TwoThousandElevenIssuanceMember 2012-01-01 2012-12-31 0001001316 tgtx:ImpairmentChargeMember 2012-01-01 2012-12-31 0001001316 2012-12-31 0001001316 tgtx:IconClinicalResearchMember 2012-12-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember 2012-12-31 0001001316 us-gaap:SeriesAPreferredStockMember 2012-12-31 0001001316 us-gaap:CommonStockMember 2012-12-31 0001001316 tgtx:NonControllingInterestInSubsidiaryMember 2012-12-31 0001001316 tgtx:UsFederalIncomeTaxMember 2012-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001001316 us-gaap:PreferredStockMember 2012-12-31 0001001316 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0001001316 us-gaap:CommonStockMember 2012-12-31 0001001316 us-gaap:ContingentlyIssuableSharesMember 2012-12-31 0001001316 tgtx:LfbGroupMember 2012-12-31 0001001316 tgtx:AristonMember 2012-12-31 0001001316 tgtx:IconConvertibleNotesMember 2012-12-31 0001001316 us-gaap:FairValueInputsLevel1Member 2012-12-31 0001001316 tgtx:StockOptionPlanMember 2012-12-31 0001001316 tgtx:NoninterestbearingMember 2012-12-31 0001001316 us-gaap:FairValueInputsLevel2Member 2012-12-31 0001001316 us-gaap:FairValueInputsLevel3Member 2012-12-31 0001001316 tgtx:ConvertibleNotesMember 2012-12-31 0001001316 us-gaap:TreasuryStockMember 2012-12-31 0001001316 tgtx:CorporateMileStoneMember 2012-12-31 0001001316 us-gaap:FairValueInputsLevel1Member tgtx:NonrecurringMember 2012-12-31 0001001316 us-gaap:FairValueInputsLevel2Member tgtx:NonrecurringMember 2012-12-31 0001001316 us-gaap:FairValueInputsLevel3Member tgtx:NonrecurringMember 2012-12-31 0001001316 tgtx:StockOptionPlan1995Member 2012-12-31 0001001316 tgtx:IncentivePlanMember 2012-12-31 0001001316 tgtx:NonEmployeeRestrictedStockMember 2012-12-31 0001001316 tgtx:PlacementAgentMember 2012-12-31 0001001316 tgtx:ResearchDevelopmentExpensesMember 2012-12-31 0001001316 tgtx:ExchangeTransactionMember 2012-12-31 0001001316 tgtx:ImpairmentChargeMember 2012-12-31 0001001316 2011-12-01 2012-12-31 0001001316 2013-03-01 0001001316 2011-11-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure TG THERAPEUTICS, INC. 0001001316 --12-31 Smaller Reporting Company tgtx 25820738 10-K false 2012-12-31 FY 2012 No No Yes 69293694 0 0 9748491 16455995 0 1990759 87176 29128 9835667 18475882 0 1164 3902300 5441839 3902300 2797600 0 0 2797600 -1104700 799391 629752 799391 799391 14537358 22074037 877778 677778 677778 200000 0 677778 677778 677778 0 0 666640 1117397 0 145000 0 152381 61941 123511 1606359 2216067 0 1828571 3294797 4664697 3294797 2479098 4901156 6523736 413 0 5061 25821 6 6 10472115 34534805 0 85000 84538 853074 18925793 9624521 15550301 11681 0 9636202 11681 10472115 413 -853074 5061 6 15550301 0 34534805 0 -18925793 25821 6 -84538 14537358 22074037 0.001 0.001 10000000 10000000 413388 0 413388 0 8267760 0 0.001 0.001 500000000 500000000 5061399 25820738 5061399 25820738 0 13526 0 19048 19048 297000 16578000 16875000 0 455809 134000 455809 30283 0 3994182 1447000 4024465 327283 21027991 21355274 86494 2966373 3052867 468197 1815083 2283280 554691 4781456 5336147 0 1104700 1104700 1104700 881974 26914147 27796121 -881974 -26895099 -27777073 0 15787 15787 0 272232 272232 7097 905744 912841 0 1659872 1659872 -7097 1042147 1035050 -889071 -25852952 -26742023 0 330000 330000 -889071 -35997 -853074 -26182952 -8110233 -18072719 -27072023 -35997 -8110233 -8146230 -853074 -18072719 -18925793 -0.44 -1.38 1926198 13113758 413388 5061399 0 25820738 13526 106578 104078 2500 2500000 297000 296868 132 132000 322964 47678 277500 281 -2501 6 281250 -2500124 55271 55268 3 2763 0 1021 129 -1150 129375 -1150000 4929523 695428 2000000 9655816 9650886 4930 12181406 12180710 696 16578000 16578000 0 -8749 -1109 9858 7500000 -1108816 9857596 1150 1150 0 -5902 5902 1150000 5901743 5000000 0 -8479448 8474448 5000 -84538 -84538 13526 2.25 2.25 2.25 20 86494 3422182 3508676 -297000 -16578000 -16875000 0 235 235 0 -815699 -815699 -3593 1932710 1929117 408310 595757 1004067 7097 61571 68668 0 1980952 1980952 -86577 -5187964 -5274541 0 1399 1399 10386 0 10386 10386 -1399 8987 275188 0 200001 200001 9824682 0 9824682 0 12257309 12257309 0 75903 75903 0 -84538 -84538 9824682 11896867 21721549 9748491 6707504 16455955 55271 0 55271 61138 0 61138 <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>DESCRIPTION OF BUSINESS</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently, the Company is developing therapies targeting hematological malignancies.<font style="font: 10pt times new roman, times, serif; color: #333333;"></font>TG-1101 (ublituximab), is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B₁₂ deficiency.&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Exchange Transaction with TG Therapeutics, Inc. and its majority shareholders</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 29, 2011, the Company entered into and consummated an Exchange Transaction Agreement with Opus Point Partners, LLC (&#8220;Opus&#8221;) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (&#8220;TG Bio&#8221;) (the &#8220;Agreement&#8221;). Under the Agreement, Opus exchanged (the &#8220;Exchange Transaction&#8221;) its shares of common stock in TG Bio (&#8220;TG Bio Common Stock&#8221;) for shares of Series A preferred stock in the Company (&#8220;Company Preferred Stock&#8221;). In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio&#8217;s shareholders 281,250 shares of Company Preferred Stock. <font style="background-color: white; color: black;">Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed below), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. </font>The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&#8217;s outstanding Company Common Stock immediately following the consummation of the transaction.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Since the stockholders of TG Bio received the majority of the voting shares of the Company, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;) include the historical financial results of TG Bio and will hereafter collectively be referred to as the Company.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (&#8220;Manhattan&#8221;) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>CORRECTION OF AN IMMATERIAL ERROR</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has identified certain immaterial errors in its previously issued consolidated financial statements for the year ended December 31, 2011. In connection with the Exchange Transaction (see description above), a valuation using the guidance in the accounting literature for business combinations was performed to determine the fair value of the assets acquired and liabilities assumed. The Company has determined that certain methodologies and assumptions utilized in this valuation were incorrect. As a result of this, the Company has recorded an adjustment to previously reported in-process research and development, goodwill, and notes payable, less current portion, at fair value, at December 31, 2011 as follows:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td><td>In-process research and development decreased from $5,441,839 to $3,902,300</td></tr></table><table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td><td>Goodwill increased from $629,752 to $799,391</td></tr></table><table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;"></td><td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td><td>Notes payable, less current portion, at fair value decreased from $4,664,697 to $3,294,797</td></tr></table><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The net effect of this adjustment is a decrease to total assets and liabilities, as previously reported, of $1,369,900.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The adjustment was recorded as of December 31, 2011 and has no effect on the statement of operations or statement of equity for any period. The Company assessed the impact of this adjustment under the provisions of SEC Staff Accounting Bulletin Nos. 99 and 108 and determined the impact of the errors to be immaterial to the financial statements. The accompanying consolidated balance sheet as of December 31, 2011 reflects the corrections of the aforementioned immaterial errors.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We have incurred operating losses since our inception, and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of December 31, 2012, we have an accumulated deficit of $18,925,793.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our primary source of cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, we had $16,455,995 in cash and cash equivalents. We currently anticipate that our cash and cash equivalents to be sufficient to fund our anticipated operating cash requirements for approximately 18 months from December 31, 2012. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our common stock is quoted on <font style="color: black;">the OTC Bulletin Board<font style="font-family: times new roman, times, serif;"></font></font>and trades under the symbol &#8220;TGTX.&#8221;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>REVERSE STOCK SPLIT</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;">On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Annual Report on Form 10-K have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty-six and one quarter (56.25) for one (1) basis, unless otherwise indicated.&#160;&#160;The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty-six and one quarter (56.25).</font></p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>2011 MANAGEMENT CHANGES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction with TG Therapeutics, Inc., effective December 29, 2011, Douglas Abel, David C. Shimko and Richard Steinhart resigned from their positions on the Board of Directors of the Company.&#160;&#160;Michael McGuinness resigned both his seat as a director and as an officer of the Company, effective December 29, 2011.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Effective December 29, 2011, Michael S. Weiss was appointed Executive Chairman, Interim Chief Executive Officer and President of the Company. In connection with the appointment, the Company assumed Mr. Weiss&#8217; employment agreement with TG, effective November 1, 2011, under which Mr. Weiss is to serve as the Company&#8217;s Executive Chairman, Interim Chief Executive Officer and President until such employment is terminated pursuant to the terms of the agreement.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction and the appointment of Mr. Weiss to his position, the Company issued replacement awards and granted 112,500 shares of Series A Preferred Stock, to Mr. Weiss on December 29, 2011. <font style="background-color: white; color: black;">Each share of Series A Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. </font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Under the terms of his employment agreement, on an annual basis, the Company will also grant Mr. Weiss a number of shares of restricted common stock equal to 1.25% of the shares of Common Stock outstanding on the date of grant on a fully-diluted basis. Each of these annual grants of restricted stock will vest and become non-forfeitable as to 25% of the shares on the first anniversary of the respective date of grant, as to 25% of the shares on the second anniversary of the respective date of grant and as to 50% of the shares on the date that the &#8220;market capitalization&#8221; (as defined in the employment agreement) is $100 million greater than the market capitalization on the respective date of grant, provided that Mr. Weiss remains an employee, director and/or consultant of the Company through each vesting date.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Effective December 29, 2011, Sean A. Power was appointed Chief Financial Officer, Treasurer and Secretary of the Company.&#160;In connection with the appointment, the Company assumed Mr. Power&#8217;s employment agreement with TG, effective November 1, 2011, under which Mr. Power is to serve as the Company&#8217;s Chief Financial Officer, Treasurer and Secretary until such employment is terminated pursuant to the terms of the agreement.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction and the appointment of Mr. Power to his position, the Company issued replacement awards and granted 16,875 shares of Series A Preferred Stock, to Mr. Power on December 29, 2011. <font style="background-color: white; color: black;">Each share of Series A Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock.</font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company will grant Mr. Power a number of shares of restricted common stock of the Company as determined by the CEO and board. Each of these annual grants of restricted stock will be subject to vesting terms, which will be determined at the time of grant by the CEO and Board.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>RECENTLY ISSUED ACCOUNTING STANDARDS</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In February 2013, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued amendments to the accounting guidance for presentation of comprehensive income to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments do not change the current requirements for reporting net income or other comprehensive income, but do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where the net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about these amounts. These amendments are effective prospectively for reporting periods beginning after December 15, 2012. The Company does not believe the adoption of this guidance will have a material impact on the consolidated financial statements.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>BASIS OF PRESENTATION</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 27pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has generated limited revenue from its operations and, accordingly, the financial statements have been prepared in accordance with the provisions of accounting and reporting for Development Stage Enterprises.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>USE OF ESTIMATES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>CASH AND CASH EQUIVALENTS</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>REVENUE RECOGNITION</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1)&#160;the milestone payment is non-refundable, (2)&#160;substantive effort is involved in achieving the milestone, (3)&#160;the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4)&#160;the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>RESEARCH AND DEVELOPMENT COSTS</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>IN-PROCESS RESEARCH AND DEVELOPMENT</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><p style="text-indent: 27pt; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;">All acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed as of the balance sheet date to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment is tested on an annual basis, and consists of a comparison of the fair value of the in-process research and development with its carrying amount.</font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>INCOME TAXES</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than &#8220;more likely than not,&#8221; a valuation allowance is then created.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize interest and penalties related to uncertain income tax positions in income tax expense.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>STOCK - BASED COMPENSATION</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize all share-based payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For share-based payments to consultants and other third-parties, compensation expense is determined at the &#8220;measurement date.&#8221; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic net income (loss) per common share is calculated by dividing net income (loss) applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net income (loss) per common share, since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 10,746,837 and 5,320,173 at December 31, 2012 and 2011, respectively. During the years ended December 31, 2012 and 2011 the Company incurred a net loss, therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;"></font>&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>LONG LIVED ASSETS AND GOODWILL</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;">Long lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management&#8217;s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.</font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;"></font>&#160;&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&#8217;s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit&#8217;s goodwill is compared with the carrying amount of the unit&#8217;s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 2 &#8211; CASH AND CASH EQUIVALENTS </b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2012</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 72%; padding-right: 0px; font-size: 10pt;">Checking and bank deposits</td><td style="padding-bottom: 1pt; font-style: normal; width: 2%; font-size: 10pt; font-weight: normal;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">$</td><td style="border-bottom: black 1pt solid; text-align: right; font-style: normal; width: 10%; font-size: 10pt; font-weight: normal;">16,455,995</td><td style="text-align: left; padding-bottom: 1pt; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">&#160;</td><td style="padding-bottom: 1pt; font-style: normal; width: 2%; font-size: 10pt; font-weight: normal;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">$</td><td style="border-bottom: black 1pt solid; text-align: right; font-style: normal; width: 10%; font-size: 10pt; font-weight: normal;">9,748,491</td><td style="text-align: left; padding-bottom: 1pt; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">16,455,995</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">9,748,491</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 3 <font style="font-family: times new roman, times, serif;">&#8211; FAIR VALUE MEASUREMENTS</font></b></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td> <td>Level 1 &#8211; quoted prices in active markets for identical assets and liabilities;</td> </tr> </table> <p style="margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td> <td>Level 2 &#8211; inputs other than Level 1 quoted prices that are directly or indirectly observable; and</td> </tr> </table> <p style="margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td> <td>Level 3 &#8211; unobservable inputs that are not corroborated by market data.</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012 and 2011, the fair values of cash and cash equivalents, and notes and interest payable, current portion approximate their carrying value.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;">Upon the merger between Manhattan and Ariston Pharmaceuticals, Inc. (&#8220;Ariston&#8221;) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the &#8220;5% Notes&#8221;) in satisfaction of several note payable issuances.&#160;&#160;The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.&#160;&#160;Ariston agreed to make quarterly payments on the 5% Notes&#160;equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&#8217;s product candidates, AST-726 and AST-915.&#160;&#160;The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&#8217;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.</font></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. <font style="background-color: white; color: black;">The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $17,727,000 and $16,883,000 at December 31, 2012 and 2011, respectively. </font>As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on these notes as of December 31, 2012.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We elected the fair value option for valuing the 5% Notes upon the completion of the reverse merger with TG Bio, as discussed above. The Company elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.<font style="background-color: white; color: black;"></font></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The valuation method used to estimate the 5% Notes&#8217; fair value was a discounted cash flow model, where the expected cash flows of AST-726 and AST-915 are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at December 31, 2012 and 2011. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s financial liabilities measured at fair value on a recurring basis as of December 31, 2012 and 2011 were as follows:</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="14">Financial liabilities at fair value <br />as of December 31, 2012</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 1</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 2</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 3</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Total</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 44%; padding-right: 0px; font-size: 10pt;">5% Notes</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">2,479,098</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">2,479,098</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Totals</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,479,098</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,479,098</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font: 10pt times new roman, times, serif;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="14">Financial liabilities at fair value <br />as of December 31, 2011</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 1</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 2</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 3</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Total</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 44%; padding-right: 0px; font-size: 10pt;">5% Notes</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">3,294,797</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">3,294,797</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Totals</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,294,797</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,294,797</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2011 and 2012:</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 70%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Balance at January 1, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0.12in; width: 84%; padding-right: 0px; font-size: 10pt;">Transfer into Level 3</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 12%; font-size: 10pt;">3,287,700</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Interest accrued on face value of 5% Notes</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">7,097</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Change in fair value of Level 3 liabilities</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Balance at December 31, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">3,294,797</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Interest accrued on face value of 5% Notes</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">844,173</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Change in fair value of Level 3 liabilities</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(1,659,872)</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Balance at December 31, 2012</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,479,098</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying consolidated statements of operations.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Nonrecurring Fair Value Measurements</i></b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s assets measured at fair value on a nonrecurring basis as of December 31, 2012 were as follows:</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="10" nowrap="nowrap">Fair value measurements <br />as of December 31, 2012</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Level 1</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Level 2</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Level 3</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Total impairment charge<br />for the year ended<br />December 31, 2012</b></td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt; font-weight: bold;">Assets:</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 36%; padding-right: 0px; font-size: 10pt;">In-process research and development</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">2,797,600</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">(1,104,700</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Total</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,797,600</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">(1,104,700</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">)</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As a result of market changes affecting the commercial potential for the Ariston in-process research and development assets (AST-726 and AST-915), the Company determined that the asset's carrying value was no longer fully recoverable. Accordingly, during the year ended December 31,&#160;2012, we recorded a non-cash impairment charge of&#160;approximately $1,104,700, which was recorded as impairment of in-process research and development in our consolidated statements of operations. The fair value of this asset was determined using a discounted cash flow model, where the expected cash flows of the Ariston assets are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. This fair value measurement technique is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the market or any of the assumptions used in determining the fair value of this asset may result in a further reduction to its estimated fair value and could result in additional and potentially full future impairment charges. Also contributing to the impairment charge was the Company&#8217;s decision during the year ended December 31, 2012 to discontinue future development activities for AST-915, following the analysis from a Phase I dose escalation trial, in which AST-915 failed to meet its primary efficacy endpoint.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 4 <font style="font-family: times new roman, times, serif;">&#8211; ACQUISITION</font></b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 29, 2011, the Company completed a reverse acquisition of privately held TG Bio, a Delaware Corporation. The acquisition was effected pursuant to an Exchange Transaction Agreement (the &#8220;Agreement&#8221;) dated December 29, 2011 by and among the Company, TG Bio and Opus, the largest shareholder of TG Bio. In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio&#8217;s shareholders 281,250 shares of Company Preferred Stock. <font style="background-color: white; color: black;">Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. </font>The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&#8217;s outstanding Company Common Stock immediately following the consummation of the transaction.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The shares of Common Stock issued upon the conversion of the Company Preferred Stock are not registered for resale and, therefore, shall remain subject to the rights and restrictions of Rule 144 under the Securities Act of 1933, as amended.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Based on fair value of the Company&#8217;s Common Stock of $2.25 per share at December 29, 2011, the purchase price was $295,933, plus the fair value of restricted stock assumed of $82,305. In connection with the Exchange Transaction, the Company incurred $231,580 of acquisition related costs.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of the purchase price calculation is as follows:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 72%; padding-right: 0px; font-size: 10pt;">Number of shares of Manhattan common stock outstanding at the time of the transaction</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">131,526</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Multiplied by Manhattan&#8217;s fair value of the Common Stock</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">2.25</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">$</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">295,933</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Fair value of restricted stock assumed</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">82,305</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Total purchase price</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font: 10pt times new roman, times, serif;">378,238</td><td style="text-align: left; padding-bottom: 2.5pt; font: 10pt times new roman, times, serif;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The purchase price has been allocated as follows based on the fair values of the assets and liabilities acquired:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 86%; padding-right: 0px; font-size: 10pt;">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">10,386</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Other assets</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">90,770</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">In-process research and development acquired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">3,902,300</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Total identifiable assets</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">4,003,456</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Accounts payable and accrued expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">197,191</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Notes payable (ICON and Swiss Pharma)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">939,718</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">5% notes payable and accrued interest</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">3,287,700</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Total identifiable liabilities</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">4,424,609</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Net identifiable assets (liabilities)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(421,153</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Goodwill</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">799,391</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">378,238</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of certain identifiable intangible assets was determined using the income approach. This method starts with a forecast of the expected future net cash flows. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk of achieving the asset&#8217;s projected cash flows. The present value of the estimated cash flows are then added to the present value equivalent of the residual value of the asset, if any, at the end of the discrete projection period to estimate the fair value.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The valuations are based on information that is available as of the acquisition date and the expectations and assumptions that have been deemed reasonable by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will occur as projected. For these reasons, among others, the actual results may vary from the projected results.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following supplemental pro forma information for the year ended December 31, 2011 presents the financial results as if the transaction had occurred on January 1, 2011.&#160;This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future results.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: -0.5in; padding-left: 0.5in; font-size: 10pt;">Revenue</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.5in; padding-left: 0.5in; width: 84%; font-size: 10pt;">Net loss</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 12%; font-size: 10pt;">(818,279</td><td style="text-align: left; width: 1%; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Basic and diluted loss per common share</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">(0.31</td><td style="text-align: left; font-size: 10pt;">)</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 5 <font style="font-family: times new roman, times, serif;">&#8211; </font>STOCKHOLDERS&#8217; EQUITY</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Preferred Stock</i></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, <font style="background-color: white; color: black;">issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. </font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white; color: black;">There were 413,388 shares of preferred stock outstanding as of December&#160;31, 2011. </font>In connection with the Exchange Transaction with TG Therapeutics, Inc., on December 29, 2011, the Company filed a Certificate of Designation with respect to its Series A Preferred Stock with the Secretary of State of the State of Delaware.&#160;&#160;The Company Preferred Stock ranks senior to the Company Common Stock with regard to dividend rights, and has a liquidation preference of $20 per share over the Company Common Stock and any other junior securities.&#160;The Company Preferred Stock is automatically convertible into 500 shares of Company Common Stock provided that prior to conversion, the Company has sufficient authorized Company Common Stock to effect such conversion.&#160;&#160;In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding Company Preferred Stock automatically converted to 9,857,596 shares of Common Stock as of that date.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Common Stock</i></b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our amended and restated certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 30, 2011, we <font style="color: black;">completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &#8220;2011 Equity PIPE&#8221;).&#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years. </font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. E<font style="background-color: white;">ach share of Company Preferred Stock was convertible into 8.89 shares of Common Stock; provided that such conversion rights were subject to sufficient available authorized shares of Common Stock.</font><font style="background-color: white;">In connection with the reverse stock split effected by the Company on April 30, 2012, all shares of Preferred Stock issued in the 2011 Equity PIPE were converted to Common Stock.</font> Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&#160;<font style="background-color: white;">The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section&#160;4(2) of the Securities Act, and Regulation&#160;D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The placement agent received cash commissions equal to 10% of the gross proceeds of the offering, five-year warrants to purchase shares of the Company&#8217;s stock equal to 10% of shares sold in the offering, and a non-accountable expense allowance equal to two percent of the gross proceeds of the offering for their expenses.&#160;&#160;&#160;&#160;</font></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Treasury Stock</i></b></p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 17, 2012, our Chief Financial Officer surrendered to the Company 13,526 shares of common stock in order to satisfy his tax withholding obligation upon the vesting of 37,500 shares of restricted stock. The 13,526 shares of common stock are being held by the Company in Treasury, at a cost of approximately $85,000, representing the fair market value on the date the shares were surrendered.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Equity Incentive Plans</i></b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We have in effect the following stock option and incentive plans.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">a. <font style="font-size: 10pt;">In July 1995, the Company established the 1995 Stock Option Plan (the &#8220;1995 Plan&#8221;), which provided for the granting of options to purchase up to 2,600 shares of the Company&#8217;s common stock to officers, directors, employees and consultants. The 1995 Plan was amended several times to increase the number of shares reserved for stock option grants. In June 2005, the 1995 Plan expired and no further options can be granted. At December 31, 2012, options to purchase 313 shares were outstanding and no shares were reserved for future stock option grants under the 1995 Plan.</font></p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">b. The Company has shareholder-approved incentive stock option plans for employees under which it has granted non-qualified and incentive stock options. At December 31, 2012, 5,333 shares were authorized for issuance. The options have a maximum term of 10 years and vest over a period determined by the Company&#8217;s Board of Directors (generally 3 years) and are issued at an exercise price equal to or greater than the fair market value of the shares at the date of grant. At December 31, 2012, options to purchase 591 shares were outstanding, 10 shares of common stock were issued and there were 4,732 shares reserved for future grants under the Plan.</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; c. In May 2012, the Company established the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (&#8220;2012 Incentive Plan&#8221;). Under the 2012 Incentive Plan, the compensation committee of the Company&#8217;s board of directors is authorized to grant stock-based awards to directors, consultants, employees and officers. The 2012 Incentive Plan authorizes grants to purchase up to 6,000,000 shares of authorized but unissued common stock. As of December 31, 2012, options to purchase 46,000 shares were outstanding and up to an additional 2,052,257 shares may be issued under the 2012 Incentive Plan.</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Stock Options</u></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes stock option activity for the years ended December 31, 2012 and 2011:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Number<br />of shares</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Weighted-<br />average<br />exercise price</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Weighted-<br />average<br />Contractual<br />Term</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Aggregate<br />Intrinsic<br />Value</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-style: normal; font-size: 10pt;">&#160;</td><td style="text-align: right; font-style: normal; font-size: 10pt;" colspan="2">&#160;</td><td style="font-style: normal; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">(in years)</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at January 1, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.24in; width: 44%; padding-right: 0px; font-size: 10pt;">Assumed in Exchange Transaction</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">4,143</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">1,375.18</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">5.60</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Exercised</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(364</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">197.34</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Expired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(400</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">2,951.12</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2011</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">3,379</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1,315.62</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">6.39</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">46,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">4.40</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Exercised</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,475</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">720.45</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Expired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">46,904</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">61.08</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">9.44</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Vested and expected to vest at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">904</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,945.09</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1.73</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Exercisable at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">898</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,963.46</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1.70</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, the total compensation cost related to unvested time-based option awards not yet recognized is less than $1,000. The weighted average period over which it is expected to be recognized is approximately 3 months. This amount does not include, as of December 31, 2012, 46,000 non-employee options outstanding which are milestone-based and vest upon certain corporate milestones. Stock-based compensation will be measured and recorded if and when a milestone occurs.</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Restricted Stock- Preferred</u></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain employees had been awarded restricted preferred stock. The restricted stock vesting consisted of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2012 and 2011:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font: 10pt times new roman, times, serif;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Number of Shares<br />Restricted Series<br />A Preferred<br />Stock<font style="font-family: times new roman, times, serif;">⁽¹⁾</font></b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Weighted<br />Average<br />Grant Date<br />Fair Value</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at January 1, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; width: 68%; padding-right: 0px; font-size: 10pt;">Granted</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 12%; font-size: 10pt;">129,375</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 12%; font-size: 10pt;">20.00</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Vested</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">129,375</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">20.00</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Vested</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Conversion to restricted common stock</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(129,375</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">20.00</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: -1pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: -1pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font: 10pt times new roman, times, serif;"><b><u>⁽</u>¹⁾</b></font>The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of preferred stock was convertible into 8.89 shares of the Company&#8217;s Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Restricted Stock- Common</u></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain employees, directors and consultants have been awarded restricted Company Common Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2012 and 2011:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt times new roman, times, serif;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Number of Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Weighted<br />Average<br />Grant Date<br />Fair Value</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="font-size: 10pt;">Outstanding at January 1, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Vested</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Forfeited</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="font-size: 10pt;">Outstanding at December 31, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-left: 0.24in; width: 68%; font-size: 10pt;">Converted preferred stock</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 12%; font-size: 10pt;">1,150,000</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 12%; font-size: 10pt;">2.25</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,901,743</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">4.77</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Vested</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(437,500</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">2.25</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Forfeited</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; font-size: 10pt;">Outstanding at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">6,614,243</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">4.49</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: -1pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Total expense associated with restricted stock grants (both common and preferred) was $3,422,182 and $86,494 during the years ended December 31, 2012 and 2011, respectively. As of December 31, 2012, there was approximately $8,941,000 of total unrecognized compensation cost related to non-vested time based restricted stock, which is expected to be recognized over a weighted-average period of 2.8 years. This amount does not include, as of December 31, 2012, 2,092,500 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,580,000 shares of restricted stock outstanding issued to non-employees (see Note 10 &#8211; Related Party Transactions for additional information). Milestone based non-cash compensation expense will be measured and recorded if and when a milestone occurs.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Warrants</u></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes warrant activity for the years ended December 31, 2012 and 2011:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">Warrants</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted-<br />average<br />exercise price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="font-size: 10pt;">Outstanding at January 1, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-left: 0.24in; width: 58%; font-size: 10pt;">Assumed in Exchange Transaction</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">393,437</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">14.74</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Issued</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,232,474</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">2.25</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Exercised</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Expired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; font-size: 10pt;">Outstanding at December 31, 2011</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1,625,911</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">5.27</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Issued</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,156,599</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1.21</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-left: 0.24in; font-size: 10pt;">Exercised</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Expired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(1,503</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">2,739.75</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; font-size: 10pt;">Outstanding at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">6,781,007</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.58</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">14,563,539</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As discussed above, as part of the 2011 Equity PIPE, we issued warrants to purchase up to 2,777,962 shares of our common stock, none of which have been exercised as of December 31, 2012. The warrants have an exercise price of $2.25 per warrant share. In addition, we issued to the placement agent in the transaction warrants to purchase up to 1,111,111 shares of our common stock at an exercise price of $2.48 per warrant share, none of which have been exercised as of December 31, 2012.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Securities Exchange Agreement between the Company and LFB Group as discussed in Note 8 &#8211; License Agreements, we issued LFB Group a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock-Based Compensation</i></b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the year-ended December 31, 2011.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2012 and 2011:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -14.2pt; padding-left: 14.2pt; width: 72%; font-size: 10pt;">Stock-based compensation expense associated with restricted stock</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">3,422,182</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">86,494</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt; font-size: 10pt;">Stock-based compensation expense associated with option grants</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,422,182</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">86,494</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Non-controlling Interest</i></b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On November 9, 2012, LFB Group exercised their right to exchange their TG Bio common stock for Company Common Stock. The Company and LFB Group entered into a Securities Exchange Agreement pursuant to which, LFB Group agreed to exchange its 7,500,000 shares of the common stock of TG Bio, for 5,000,000 shares of Company Common Stock, and a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share. Refer to </font>Note 8 &#8211; License Agreements for further information.</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accordingly, in connection with the aforementioned Securities Exchange Agreement, TG Bio became a wholly owned subsidiary of the Company. Prior to the execution of the Securities Exchange Agreement LFB Group owned approximately 42.9% of TG Bio.<font style="background-color: white;"> The non-controlling interest in subsidiary balance was approximately $8,479,000 immediately prior to LFB Group exercising their option, which was transferred to equity in connection with the transaction.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 6 &#8211; NOTES PAYABLE</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">The following is a summary of notes payable:</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="10" nowrap="nowrap"><font style="font-size: 8pt;">December 31, 2012</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="10" nowrap="nowrap"><font style="font-size: 8pt;">December 31, 2011</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Current<br />portion, net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Non-<br />current<br />portion,<br />net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Total</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Current<br />portion,<br />net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Non-<br />current<br />portion,<br />net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Total</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 40%; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">Non-interest Bearing Note Payable, Net</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">--</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">--</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">200,000</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">200,000</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">Convertible 5% Notes Payable</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">2,479,098</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">2,479,098</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,294,797</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,294,797</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">ICON Convertible Note</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">Total</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">2,479,098</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,156,876</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">877,778</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,294,797</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">4,172,575</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr></table><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We assumed the preceding notes payable as the result of the Exchange Transaction between the Company and TG Therapeutics, Inc. Accordingly, a valuation using the guidance in the accounting literature for business combinations (ASC 805) was performed and these notes have been presented at their fair value on the date of the transaction.</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Non-interest Bearing Note Payable</i></b></p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">In October 2009, Manhattan entered into a Settlement Agreement and Mutual Release with Swiss Pharma Contract LTD (&#8220;Swiss Pharma&#8221;) pursuant to which Manhattan agreed to pay Swiss Pharma $200,000 and issue to Swiss Pharma an interest free promissory note due on October 27, 2011 in the principal amount of $250,000 in full satisfaction of a September 5, 2008 arbitration award. In November 2011, Manhattan renegotiated the $250,000 promissory note in which the amount of the promissory note was reduced to $200,000 and the maturity date was extended to February 15, 2012. This amount was paid on February 14, 2012 in full settlement of this note.</p><p style="text-indent: 0.5in; margin: 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Convertible 5% Notes Payable</i></b></p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub").&#160; Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger.&#160; As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.&#160;&#160;Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&#8217;s product candidates, AST-726 and AST-915.&#160;&#160;<font style="background-color: white; color: black;">The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&#8217;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.</font> Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which is March 8, 2015.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. <font style="background-color: white; color: black;">The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $17,727,000 and $16,883,000 at December 31, 2012 and 2011, respectively. </font>As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on these notes as of December 31, 2012. See Note 3 for further details.</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>ICON Convertible Note Payable</i></b></p><p style="text-indent: 0.5in; margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the merger with Ariston as discussed above, Ariston satisfied an account payable of $1,275,188 to ICON Clinical Research Limited (&#8220;ICON&#8221;) through the payment of $275,188 in cash and the issuance of a three-year 5% note payable (the &#8220;ICON Note&#8221;).&#160;&#160;The principal was to be repaid in 36 monthly installments of $27,778 commencing in April 2010.&#160;&#160;Interest was payable monthly in arrears. &#160;&#160;On March 1, 2011 Ariston entered into an amended and restated convertible promissory note (the &#8220;Amended ICON Note&#8221;) with ICON. The principal terms of the Amended ICON Note are that monthly payments of principal and interest will be waived for the thirteen month period ended December 31, 2011 (the &#8220;Waiver Period&#8221;) in exchange for a single payment of $100,000 on March 31, 2011, an increase in the interest on the Amended ICON Note from 5% to 8% per annum during the Waiver Period and a balloon payment on January 31, 2012. The Amended ICON Note is convertible at the option of the holder into the Company&#8217;s common stock at the conversion price of $562.50 per share. During the year ended December 31, 2012, the Company recorded $61,571 of interest expense on the Amended ICON Note. As of December 31, 2012 and 2011, the principal amount of the Amended ICON Note was $677,778, of which the entire balance has been classified as current and is reflected as notes payable, current portion, net in the accompanying consolidated balance sheets. Interest payable on the Amended ICON Note was $123,511 and $61,941 as of December 31, 2012 and 2011, respectively, and is reflected as interest payable, current portion, net in the accompanying consolidated balance sheets. This note is currently in default as the Company did not make the balloon payment due on January 31, 2012, or any subsequent payments. The Company is currently attempting to negotiate a settlement or alternative arrangement in satisfaction of this note.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 7 &#8211; INCOME TAXES </b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal;">We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management's assessment of all available evidence, we believe that it is more-likely-than-not that the deferred tax assets will not be realizable; and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $36,271,000 and $29,408,000 as of December 31, 2012 and 2011, respectively. </font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, we have U.S. net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $83,637,000. For income tax purposes, these NOLs will expire in various amounts through 2032. The Tax Reform Act of 1986 contains provisions which limit the ability to utilize net operating loss carryforwards in the case of certain events including significant changes in ownership interests. The Exchange Transaction with TG Bio may have resulted in a &#8220;change in ownership&#8221; as defined by IRC Section 382 of the Internal Revenue Code of 1986, as amended. Accordingly, a substantial portion of the Company&#8217;s NOLs above may be subject to annual limitations in reducing any future year&#8217;s taxable income.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2012 and 2011 are presented below.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2012</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt; font-size: 10pt;">Deferred tax assets (liabilities):</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 72%; font-size: 10pt;">Net operating loss carryforwards</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">32,190,080</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">27,611,000</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Research and development credit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,882,238</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,858,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Non-cash compensation</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">3,051,920</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,735,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Acquired in-process research and development</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(1,202,556</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,220,000</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Foreign tax credit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">330,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Other</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">19,241</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">424,000</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -9pt; padding-left: 9pt; font-size: 10pt;">Deferred tax asset, excluding valuation allowance</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">36,270,923</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">29,408,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Less valuation allowance</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(36,270,923</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(29,408,000</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Net deferred tax assets</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company recorded $330,000 in income tax expense for the year ended December 31, 2012, as a result of South Korean taxes withheld associated with the Ildong sublicense agreement (see Note 8). There was no current or deferred income tax expense for the year ended December&#160;31, 2011. Income tax expense differed from amounts computed by applying the US federal income tax rate of 34% to pretax loss as follows:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="6">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2012</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; width: 72%; padding-right: 0px; font-size: 10pt;">Loss before income taxes, as reported in the consolidated statements of operations</td><td style="padding-bottom: 2.5pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 10%; font-size: 10pt;">(25,852,952</td><td style="text-align: left; padding-bottom: 2.5pt; width: 1%; font-size: 10pt;">)</td><td style="padding-bottom: 2.5pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 10%; font-size: 10pt;">(889,071</td><td style="text-align: left; padding-bottom: 2.5pt; width: 1%; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Computed &#8220;expected&#8221; tax benefit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">(8,790,003</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">(302,284</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Increase (decrease) in income taxes resulting from:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Expected expense (benefit) from state and local taxes</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(1,758,001</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(60,457</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Research and development credits</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(75,000</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(75,000</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Other</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">230,643</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(277</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Foreign tax withholding</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">330,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Change in the balance of the valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">10,392,361</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">438,018</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">330,000</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We file income tax returns in the U.S Federal and various state and local jurisdictions. With certain exceptions, the Company is no longer subject to U.S. Federal and state income tax examinations by tax authorities for years prior to 2009. However, NOLs and tax credits generated from those prior years could still be adjusted upon audit.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company recognizes interest and penalties to uncertain tax position in income tax expense in the statement of operations. There was no accrual for interest and penalties related to uncertain tax positions for 2012.&#160;We do not believe that there will be a material change in our unrecognized tax positions over the next twelve months.&#160;All of the unrecognized tax benefits, if recognized, would be offset by the valuation allowance.</p> <p style="text-indent: 0in; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">NOTE 8 &#8211; LICENSE AGREEMENTS</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>TG-1101</i></b></p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In April 2011, TG Bio acquired from LFB Biotechnologies, a fully owned subsidiary of France based LFB S.A., an option (the &#8220;License Option&#8221;) for exclusive worldwide rights (except France/Belgium) to develop and market ublituximab (&#8220;TG-1101&#8221;), a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. In exchange for the License Option, TG Bio issued 132,000 shares of its common stock to LFB.</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0.2in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On January 30, 2012, TG Bio exercised the License Option and </font>entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the &#8220;License Agreement&#8221;)<font style="color: black;">. </font>Under the License Agreement, we acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TG-1101 (ublituximab). To date, we have made no payments to LFB Group, who is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the License Agreement, our subsidiary TG Bio issued 7,368,000 shares of its common stock to LFB Group, and the Company agreed to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Bio to fund the development of ublituximab under the License Agreement in exchange for 7,500,000 shares of TG Bio common stock. The Company recognized approximately $16,578,000 of noncash research and development expense during the year ended December 31, 2012 in connection with the issuance of these shares. In addition, in connection with this share issuance, the Company and TG Bio provided LFB Group the option to, in its sole discretion, elect to convert its shares of TG Bio common stock into 7,500,000 shares of the Company&#8217;s Common Stock. Furthermore, should LFB Group choose to exercise the option for Company Common Stock, the Board of Directors of the Company shall appoint&#160;an individual designated by LFB Group to serve as a director of the Company until the next annual meeting of the stockholders and until his or her successor has been duly elected. Thereafter the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On November 9, 2012, LFB Group exercised their right to exchange their TG Bio common stock for Company Common Stock. The Company and LFB Group entered into a Securities Exchange Agreement pursuant to which, LFB Group agreed to exchange its 7,500,000 shares of the common stock of TG Bio, for 5,000,000 shares of Company Common Stock, and a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share. In addition, upon the occurrence of certain financing conditions, the Securities Exchange Agreement requires LFB Group to purchase at least $750,000 in additional shares of Company Common Stock at a purchase price per share equal to the then current Market Price (as defined therein). In addition on November 9, 2012, in connection with the Securities Exchange Agreement, the Board of Directors (the &#8220;Board&#8221;) of the Company appointed Dr. Yann Echelard to the Board as LFB Group&#8217;s nominee. Dr. Echelard will serve as a director until his term expires at the 2013 annual meeting of stockholders, at which time he will stand for reelection by the Company&#8217;s stockholders. Effective November 9, 2012, in connection with the aforementioned Securities Exchange Agreement, TG Bio became a wholly owned subsidiary of the Company.&#160;<br /><br /><i>TG-1101 &#8211; Ildong Sublicense</i></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd, (&#8220;Ildong&#8221;) relating to the development and commercialization of ublituximab in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize ublituximab in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">An upfront payment of $2,000,000, which was received in December 2012<font style="background-color: white; color: black;"> net of $330,000 of&#160;income tax withheld</font>, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which the Company will have certain ongoing responsibilities under the sublicense agreement. The Company recorded license revenue of approximately $19,000 and $0 for the years ended December 31, 2012 and 2011, respectively, and, at December 31, 2012 and 2011, has deferred revenue of approximately $1,981,000 and $0, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified as a current liability at December 31, 2012).</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to the Company on net sales of TG-1101 in the sublicense territory.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>TGR-1202</i></b></p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On August 15, 2012, the Company and Rhizen Pharmaceuticals S A (&#8220;Rhizen&#8221;) entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen&#8217;s lead product candidate (the &#8220;Collaboration Agreement&#8221;), a novel P13K delta inhibitor, (&#8220;TGR-1202&#8221;) (previously referred to as RP5264). The companies will jointly develop the product on a worldwide basis, excluding India, initially focusing on indications in the area of hematologic malignancies and autoimmune disease. Beyond TGR-1202, Rhizen would contribute backup molecules providing multiple opportunities for TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company will make up-front licensing payments and milestones based on early clinical development, and will be responsible for the costs of clinical development of the product through Phase II, after which the Company and Rhizen will be jointly responsible for all development costs of the product. The Company and Rhizen will each maintain an exclusive option, exercisable at specific times during development, for the Company to license the rights to TGR-1202, in which case Rhizen would be eligible to receive upfront, development, and commercialization milestone payments in addition to milestone payments and royalties tied to net sales of the product, the aggregate of which could exceed $250 million. Rhizen shall maintain rights to manufacture and supply the product to the Company, and the Company will be responsible for all clinical and regulatory development for TGR-1202 globally.</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">In connection with the Collaboration Agreement, the Company incurred upfront milestone payments of $1,000,000 during the year ended December 31, 2012, which has been included in other research and development expenses in the accompanying consolidated financial statements. </font>Rhizen is eligible to receive additional payments of up to $2,000,000 upon the successful achievement of certain clinical development milestones prior to entering profit and loss sharing for the TGR-1202 development program.&#160; Pursuant to the terms of the Collaboration Agreement, should either of the exclusive license options be exercised, Rhizen would be eligible to receive up to an aggregate of $182.5 million upon the successful achievement of certain clinical development, regulatory, and sales based milestones in addition to royalties on net sales of TGR-1202.</p> <p style="text-indent: 0in; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">NOTE 9 &#8211; JOINT VENTURE</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 19, 2011, H Pharmaceuticals K/S (the &#8220;Hedrin JV&#8221;), of which the Company was a 15% limited partner at the time, filed a demand for arbitration against Thornton &amp; Ross, LTD. (&#8220;T&amp;R&#8221;) with respect to alleged breaches by T&amp;R of an Exclusive License Agreement (the &#8220;Hedrin License&#8221;) dated June 28, 2007, which was originally entered into between the Company and T&amp;R, and which the Company assigned in 2008 to the Hedrin JV, with T&amp;R&#8217;s consent. The Hedrin JV is seeking damages from T&amp;R in the amount of approximately $7,000,000. The Company was not a party to the initial arbitration demand.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 20, 2011, T&amp;R filed an answer to the arbitration demand in which T&amp;R asserted counterclaims against the Hedrin JV for alleged breaches by the Hedrin JV of the Hedrin License and for declaratory relief that the Hedrin License was properly terminated by T&amp;R. In addition, T&amp;R impleaded an individual (who is not associated with the Company), Nordic Biotech Venture Fund II K/S (an investment fund) and the Company, demanding arbitration against them based on alleged breaches of the Hedrin License and other related claims. In December 2011, the Company was removed by the arbitrator as a party to the arbitration. T&amp;R is seeking damages of approximately $20,000,000.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Hedrin JV and T&amp;R held a mediation session in order to avoid the arbitration process. The mediation process did not produce a result. During 2011 Nordic made an additional capital contribution to the Hedrin JV in order to fund the arbitration. As a result of that capital contribution, as of December 31, 2011, the Company owned 13% interest in the Hedrin JV, and no further information has been available since that date. The arbitration process is ongoing.</p> <p style="text-indent: 0in; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">NOTE 10 &#8211; RELATED PARTY TRANSACTIONS</p><p style="text-indent: 0in; margin: 0pt 0px; font: bold 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 30, 2011, OPN Capital Markets (&#8220;OPNCM&#8221;) and its affiliated broker-dealer, National Securities Corporation (&#8220;NSC&#8221; and collectively with OPNCM, &#8220;National&#8221;), both affiliates of National Holdings Corporation (&#8220;National Holdings&#8221;), entered into a Placement Agency Agreement (the &#8220;PAA&#8221;) with the Company in connection with the initial closing of the 2011 Equity PIPE.&#160;&#160;Pursuant to the PAA, National acted as the Company&#8217;s placement agent for 2011 Equity PIPE.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Until April 2012, Michael S. Weiss was a director and Non-Executive Chairman of the Board of Directors of National Holdings.&#160;&#160;He is also a stockholder of National Holdings and, when combined with his ownership indirectly through Opus and its affiliates, beneficially owns approximately 6.7% of National Holdings, the parent company of NSC.&#160;Mr. Weiss disclaims such beneficial ownership other than to the extent of his pecuniary interest. In addition, at the time, Opus and NSC were parties to a 50/50 joint venture that shared profits from OPNCM, the investment banking division of NSC that was responsible for managing the Offering. This joint venture was dissolved in April 2012.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As placement agent, National received cash commissions equal to 10% of the gross proceeds of the 2011 Equity PIPE, five-year warrants to purchase shares of Company Preferred Stock equal to 10% of shares sold in the 2011 Equity PIPE, and a non-accountable expense allowance equal to two percent of the gross proceeds of the 2011 Equity PIPE for National&#8217;s expenses (not including up to $80,000 of National&#8217;s legal expenses and any blue sky fees, both of which the Company also reimbursed). In connection with the dissolution of the joint venture, in January 2013 National waived all rights to and surrendered to Opus the warrants discussed above. In addition to acting as placement agent, National provided advisory services in connection with the Exchange Transaction and received an advisory fee of $150,000 for such services.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Under the terms of the Company&#8217;s License Agreement with LFB Group, the Company utilizes LFB Group for certain development and manufacturing services. The Company incurred approximately $1,447,000 and $0 in such expenses during the years ended December 31, 2012 and 2011, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of December 31, 2012, the Company has approximately $56,000 recorded in accounts payable related to the aforementioned agreements with LFB Group. In conjunction with the development and manufacturing services discussed above, certain agreements between the Company and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of December 31, 2012, the Company recorded $1,719,828 in prepaid research and development for such advance payments.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: left; margin-top: 0pt; text-indent: 0.5in; font: 10pt times new roman, times, serif; margin-bottom: 0pt;">In connection with the Collaboration Agreement with Rhizen in August 2012, the Company issued Opus 2,000,000 shares of Company common stock subject to certain vesting provisions based on the progress of the joint venture and future success of the products governed by the Collaboration Agreement. The issuance of the Company Common Stock was exempt from registration under the Securities Act of 1933 pursuant to Regulation D and Rule 506 promulgated thereunder. Accordingly, the securities have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The Company recognized approximately $134,000 of noncash compensation (research and development) expense during the year ended December 31, 2012 in connection with the issuance of these shares.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>DESCRIPTION OF BUSINESS</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently, the Company is developing therapies targeting hematological malignancies.<font style="font: 10pt times new roman, times, serif; color: #333333;"></font>TG-1101 (ublituximab), is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B₁₂ deficiency.&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Exchange Transaction with TG Therapeutics, Inc. and its majority shareholders</i></b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 29, 2011, the Company entered into and consummated an Exchange Transaction Agreement with Opus Point Partners, LLC (&#8220;Opus&#8221;) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (&#8220;TG Bio&#8221;) (the &#8220;Agreement&#8221;). Under the Agreement, Opus exchanged (the &#8220;Exchange Transaction&#8221;) its shares of common stock in TG Bio (&#8220;TG Bio Common Stock&#8221;) for shares of Series A preferred stock in the Company (&#8220;Company Preferred Stock&#8221;). In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio&#8217;s shareholders 281,250 shares of Company Preferred Stock. <font style="background-color: white; color: black;">Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed below), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. </font>The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&#8217;s outstanding Company Common Stock immediately following the consummation of the transaction.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Since the stockholders of TG Bio received the majority of the voting shares of the Company, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;) include the historical financial results of TG Bio and will hereafter collectively be referred to as the Company.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (&#8220;Manhattan&#8221;) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We have incurred operating losses since our inception, and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of December 31, 2012, we have an accumulated deficit of $18,925,793.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our primary source of cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2012, we had $16,455,995 in cash and cash equivalents. We currently anticipate that our cash and cash equivalents to be sufficient to fund our anticipated operating cash requirements for approximately 18 months from December 31, 2012. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our common stock is quoted on <font style="color: black;">the OTC Bulletin Board<font style="font-family: times new roman, times, serif;"></font></font>and trades under the symbol &#8220;TGTX.&#8221;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>REVERSE STOCK SPLIT</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;">On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Annual Report on Form 10-K have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty-six and one quarter (56.25) for one (1) basis, unless otherwise indicated.&#160;&#160;The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty-six and one quarter (56.25).</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>2011 MANAGEMENT CHANGES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction with TG Therapeutics, Inc., effective December 29, 2011, Douglas Abel, David C. Shimko and Richard Steinhart resigned from their positions on the Board of Directors of the Company.&#160;&#160;Michael McGuinness resigned both his seat as a director and as an officer of the Company, effective December 29, 2011.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Effective December 29, 2011, Michael S. Weiss was appointed Executive Chairman, Interim Chief Executive Officer and President of the Company. In connection with the appointment, the Company assumed Mr. Weiss&#8217; employment agreement with TG, effective November 1, 2011, under which Mr. Weiss is to serve as the Company&#8217;s Executive Chairman, Interim Chief Executive Officer and President until such employment is terminated pursuant to the terms of the agreement.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction and the appointment of Mr. Weiss to his position, the Company issued replacement awards and granted 112,500 shares of Series A Preferred Stock, to Mr. Weiss on December 29, 2011. <font style="background-color: white; color: black;">Each share of Series A Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. </font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Under the terms of his employment agreement, on an annual basis, the Company will also grant Mr. Weiss a number of shares of restricted common stock equal to 1.25% of the shares of Common Stock outstanding on the date of grant on a fully-diluted basis. Each of these annual grants of restricted stock will vest and become non-forfeitable as to 25% of the shares on the first anniversary of the respective date of grant, as to 25% of the shares on the second anniversary of the respective date of grant and as to 50% of the shares on the date that the &#8220;market capitalization&#8221; (as defined in the employment agreement) is $100 million greater than the market capitalization on the respective date of grant, provided that Mr. Weiss remains an employee, director and/or consultant of the Company through each vesting date.</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Effective December 29, 2011, Sean A. Power was appointed Chief Financial Officer, Treasurer and Secretary of the Company.&#160;In connection with the appointment, the Company assumed Mr. Power&#8217;s employment agreement with TG, effective November 1, 2011, under which Mr. Power is to serve as the Company&#8217;s Chief Financial Officer, Treasurer and Secretary until such employment is terminated pursuant to the terms of the agreement.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction and the appointment of Mr. Power to his position, the Company issued replacement awards and granted 16,875 shares of Series A Preferred Stock, to Mr. Power on December 29, 2011. <font style="background-color: white; color: black;">Each share of Series A Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. </font><font style="background-color: white; color: black;">In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock.</font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company will grant Mr. Power a number of shares of restricted common stock of the Company as determined by the CEO and board. Each of these annual grants of restricted stock will be subject to vesting terms, which will be determined at the time of grant by the CEO and Board.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>RECENTLY ISSUED ACCOUNTING STANDARDS</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In February 2013, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued amendments to the accounting guidance for presentation of comprehensive income to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments do not change the current requirements for reporting net income or other comprehensive income, but do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where the net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about these amounts. These amendments are effective prospectively for reporting periods beginning after December 15, 2012. The Company does not believe the adoption of this guidance will have a material impact on the consolidated financial statements.</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>BASIS OF PRESENTATION</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 27pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has generated limited revenue from its operations and, accordingly, the financial statements have been prepared in accordance with the provisions of accounting and reporting for Development Stage Enterprises.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>USE OF ESTIMATES</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>CASH AND CASH EQUIVALENTS</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>REVENUE RECOGNITION</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1)&#160;the milestone payment is non-refundable, (2)&#160;substantive effort is involved in achieving the milestone, (3)&#160;the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4)&#160;the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>RESEARCH AND DEVELOPMENT COSTS</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>IN-PROCESS RESEARCH AND DEVELOPMENT</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b></b>&#160;</p><p style="text-indent: 27pt; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;">All acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed as of the balance sheet date to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment is tested on an annual basis, and consists of a comparison of the fair value of the in-process research and development with its carrying amount.</font></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>INCOME TAXES</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than &#8220;more likely than not,&#8221; a valuation allowance is then created.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize interest and penalties related to uncertain income tax positions in income tax expense.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>STOCK - BASED COMPENSATION</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize all share-based payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For share-based payments to consultants and other third-parties, compensation expense is determined at the &#8220;measurement date.&#8221; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE</b></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic net income (loss) per common share is calculated by dividing net income (loss) applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net income (loss) per common share, since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 10,746,837 and 5,320,173 at December 31, 2012 and 2011, respectively. During the years ended December 31, 2012 and 2011 the Company incurred a net loss, therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>LONG LIVED ASSETS AND GOODWILL</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;">Long lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management&#8217;s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.</font></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"><font style="font-style: normal; font-weight: normal;"></font>&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: italic 10pt times new roman, times, serif;"></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&#8217;s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit&#8217;s goodwill is compared with the carrying amount of the unit&#8217;s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.</p> <table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap">&#160;</td> <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2012</td> <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td> <td style="font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 72%; padding-right: 0px; font-size: 10pt;">Checking and bank deposits</td> <td style="padding-bottom: 1pt; font-style: normal; width: 2%; font-size: 10pt; font-weight: normal;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; font-style: normal; width: 10%; font-size: 10pt; font-weight: normal;">16,455,995</td> <td style="text-align: left; padding-bottom: 1pt; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">&#160;</td> <td style="padding-bottom: 1pt; font-style: normal; width: 2%; font-size: 10pt; font-weight: normal;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; font-style: normal; width: 10%; font-size: 10pt; font-weight: normal;">9,748,491</td> <td style="text-align: left; padding-bottom: 1pt; font-style: normal; width: 1%; font-size: 10pt; font-weight: normal;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Total</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">16,455,995</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">9,748,491</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s financial liabilities measured at fair value on a recurring basis as of December 31, 2012 and 2011 were as follows:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="14">Financial liabilities at fair value <br />as of December 31, 2012</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 44%; padding-right: 0px; font-size: 10pt;">5% Notes</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">2,479,098</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">2,479,098</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Totals</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,479,098</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,479,098</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="14">Financial liabilities at fair value <br />as of December 31, 2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 44%; padding-right: 0px; font-size: 10pt;">5% Notes</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">3,294,797</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; width: 10%; font-size: 10pt;">3,294,797</td><td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Totals</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,294,797</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,294,797</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2011 and 2012:</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 70%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Balance at January 1, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0.12in; width: 84%; padding-right: 0px; font-size: 10pt;">Transfer into Level 3</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 12%; font-size: 10pt;">3,287,700</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Interest accrued on face value of 5% Notes</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">7,097</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Change in fair value of Level 3 liabilities</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Balance at December 31, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">3,294,797</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Interest accrued on face value of 5% Notes</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">844,173</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Change in fair value of Level 3 liabilities</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(1,659,872)</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Balance at December 31, 2012</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,479,098</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s&#160;assets measured at fair value on a nonrecurring basis as of December 31, 2012 were as follows:</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="10" nowrap="nowrap">Fair value measurements <br />as of December 31, 2012</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Level 1</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Level 2</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Level 3</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Total impairment charge<br />for the year ended<br />December 31, 2012</b></td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt; font-weight: bold;">Assets:</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; width: 36%; padding-right: 0px; font-size: 10pt;">In-process research and development</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">2,797,600</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; width: 2%; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%; font-size: 10pt;">(1,104,700</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Total</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,797,600</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">(1,104,700</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">)</td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of the purchase price calculation is as follows:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 72%; padding-right: 0px; font-size: 10pt;">Number of shares of Manhattan common stock outstanding at the time of the transaction</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">131,526</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Multiplied by Manhattan&#8217;s fair value of the Common Stock</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">2.25</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">$</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">295,933</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Fair value of restricted stock assumed</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">82,305</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Total purchase price</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font: 10pt times new roman, times, serif;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font: 10pt times new roman, times, serif;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font: 10pt times new roman, times, serif;">378,238</td><td style="text-align: left; padding-bottom: 2.5pt; font: 10pt times new roman, times, serif;">&#160;</td></tr></table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The purchase price has been allocated as follows based on the fair values of the assets and liabilities acquired:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 86%; padding-right: 0px; font-size: 10pt;">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">10,386</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Other assets</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">90,770</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">In-process research and development acquired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">3,902,300</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Total identifiable assets</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">4,003,456</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Accounts payable and accrued expenses</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">197,191</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Notes payable (ICON and Swiss Pharma)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">939,718</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">5% notes payable and accrued interest</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">3,287,700</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Total identifiable liabilities</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">4,424,609</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Net identifiable assets (liabilities)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(421,153</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Goodwill</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">799,391</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">378,238</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following supplemental pro forma information presents the financial results as if the transaction had occurred on January 1, 2011 for the year ended December 31, 2011.&#160;This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future results.</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt times new roman, times, serif;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: -0.5in; padding-left: 0.5in; font-size: 10pt;">Revenue</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.5in; padding-left: 0.5in; width: 84%; font-size: 10pt;">Net loss</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 12%; font-size: 10pt;">(818,279</td><td style="text-align: left; width: 1%; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Basic and diluted loss per common share</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">(0.31</td><td style="text-align: left; font-size: 10pt;">)</td></tr></table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes stock option activity for the years ended December 31, 2012 and 2011:</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Number<br />of shares</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Weighted-<br />average<br />exercise price</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Weighted-<br />average<br />Contractual<br />Term</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"><b>Aggregate<br />Intrinsic<br />Value</b></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-style: normal; font-size: 10pt;">&#160;</td><td style="text-align: right; font-style: normal; font-size: 10pt;" colspan="2">&#160;</td><td style="font-style: normal; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">(in years)</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">&#160;</td><td style="font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at January 1, 2011</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.24in; width: 44%; padding-right: 0px; font-size: 10pt;">Assumed in Exchange Transaction</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">4,143</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">1,375.18</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">5.60</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Exercised</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(364</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">197.34</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Expired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(400</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">2,951.12</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2011</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">3,379</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"></td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1,315.62</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">6.39</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">46,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">4.40</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Exercised</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(2,475</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">720.45</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Expired</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">46,904</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">61.08</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">9.44</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Vested and expected to vest at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">904</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,945.09</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1.73</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Exercisable at December 31, 2012</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">898</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,963.46</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1.70</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain employees had been awarded restricted preferred stock. The restricted stock vesting consisted of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2012 and 2011:</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font: 10pt times new roman, times, serif;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Number of Shares<br />Restricted Series<br />A Preferred<br />Stock<font style="font-family: times new roman, times, serif;">⁽¹⁾</font></b></td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Weighted<br />Average<br />Grant Date<br />Fair Value</b></td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at January 1, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0.24in; width: 68%; padding-right: 0px; font-size: 10pt;">Granted</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 12%; font-size: 10pt;">129,375</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 12%; font-size: 10pt;">20.00</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Vested</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">129,375</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">20.00</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Granted</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Vested</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Forfeited</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.24in; padding-right: 0px; font-size: 10pt;">Conversion to restricted common stock</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(129,375</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">20.00</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Outstanding at December 31, 2012</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="text-indent: -1pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font: 10pt times new roman, times, serif;"><b><u>⁽</u>¹⁾</b></font>The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of preferred stock was convertible into 8.89 shares of the Company&#8217;s Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain employees, directors and consultants have been awarded restricted Company Common Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2012 and 2011:</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <div>&#160;</div> <table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font: 10pt times new roman, times, serif;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Number of Shares</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><b>Weighted<br />Average<br />Grant Date<br />Fair Value</b></td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="font-size: 10pt;">Outstanding at January 1, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Granted</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Vested</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Forfeited</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="font-size: 10pt;">Outstanding at December 31, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.24in; width: 68%; font-size: 10pt;">Converted preferred stock</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 12%; font-size: 10pt;">1,150,000</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 12%; font-size: 10pt;">2.25</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Granted</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">5,901,743</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">4.77</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Vested</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">(437,500</td> <td style="text-align: left; font-size: 10pt;">)</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">2.25</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Forfeited</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; font-size: 10pt;">Outstanding at December 31, 2012</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">6,614,243</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">4.49</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"></td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2012 and 2011:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -14.2pt; padding-left: 14.2pt; width: 72%; font-size: 10pt;">Stock-based compensation expense associated with restricted stock</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">3,422,182</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td><td style="width: 2%; font-size: 10pt;">&#160;</td><td style="text-align: left; width: 1%; font-size: 10pt;">$</td><td style="text-align: right; width: 10%; font-size: 10pt;">86,494</td><td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt; font-size: 10pt;">Stock-based compensation expense associated with option grants</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,422,182</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">86,494</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The following is a summary of notes payable:</p><p style="margin: 0pt 0.5in 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="10" nowrap="nowrap"><font style="font-size: 8pt;">December 31, 2012</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="10" nowrap="nowrap"><font style="font-size: 8pt;">December 31, 2011</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Current<br />portion, net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Non-<br />current<br />portion,<br />net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Total</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Current<br />portion,<br />net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Non-<br />current<br />portion,<br />net</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap"><font style="font-size: 8pt;">Total</font></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 40%; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">Non-interest Bearing Note Payable, Net</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">--</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">--</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">200,000</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="width: 2%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="text-align: right; width: 6%; font-size: 10pt;"><font style="font-size: 8pt;">200,000</font></td><td style="text-align: left; width: 1%; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">Convertible 5% Notes Payable</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">2,479,098</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">2,479,098</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,294,797</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,294,797</font></td><td style="text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">ICON Convertible Note</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">-</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;"><font style="font-size: 8pt;">Total</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">677,778</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">2,479,098</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,156,876</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">877,778</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">3,294,797</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"><font style="font-size: 8pt;">$</font></td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"><font style="font-size: 8pt;">4,172,575</font></td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"><font style="font-size: 8pt;">&#160;</font></td></tr></table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2012 and 2011 are presented below.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2012</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; font-size: 10pt;">Deferred tax assets (liabilities):</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: right; font-size: 10pt; font-weight: bold;">&#160;</td> <td style="text-align: left; font-size: 10pt; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 72%; font-size: 10pt;">Net operating loss carryforwards</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="text-align: right; width: 10%; font-size: 10pt;">32,190,080</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">$</td> <td style="text-align: right; width: 10%; font-size: 10pt;">27,611,000</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Research and development credit</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">1,882,238</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">1,858,000</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Non-cash compensation</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">3,051,920</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">1,735,000</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Acquired in-process research and development</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">(1,202,556</td> <td style="text-align: left; font-size: 10pt;">)</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">(2,220,000</td> <td style="text-align: left; font-size: 10pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Foreign tax credit</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">330,000</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Other</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">19,241</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">424,000</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; font-size: 10pt;">Deferred tax asset, excluding valuation allowance</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">36,270,923</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">29,408,000</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Less valuation allowance</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(36,270,923</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(29,408,000</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in; font-size: 10pt;">Net deferred tax assets</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> </tr> </table> <div>Income tax expense differed from amounts computed by applying the US federal income tax rate of 34% to pretax loss as follows:</div><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="6">For the year ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2012</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; width: 72%; padding-right: 0px; font-size: 10pt;">Loss before income taxes, as reported in the consolidated statements of operations</td><td style="padding-bottom: 2.5pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 10%; font-size: 10pt;">(25,852,952</td><td style="text-align: left; padding-bottom: 2.5pt; width: 1%; font-size: 10pt;">)</td><td style="padding-bottom: 2.5pt; width: 2%; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; width: 1%; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; width: 10%; font-size: 10pt;">(889,071</td><td style="text-align: left; padding-bottom: 2.5pt; width: 1%; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Computed &#8220;expected&#8221; tax benefit</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">(8,790,003</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">$</td><td style="text-align: right; font-size: 10pt;">(302,284</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">Increase (decrease) in income taxes resulting from:</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Expected expense (benefit) from state and local taxes</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(1,758,001</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(60,457</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Research and development credits</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(75,000</td><td style="text-align: left; font-size: 10pt;">)</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(75,000</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Other</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">230,643</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">(277</td><td style="text-align: left; font-size: 10pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Foreign tax withholding</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">330,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">--</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: 0px; padding-left: 0.12in; padding-right: 0px; font-size: 10pt;">Change in the balance of the valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">10,392,361</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">438,018</td><td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: 0px; padding-left: 0px; padding-right: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">330,000</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td><td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td><td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td></tr></table> 8.89 8.89 8.89 0.0125 0.25 0.25 100000000 0.50 5320173 10746837 0.95 18 months Ratio of 56.25 for 1 1369900 9748491 16455995 3294797 0 0 3294797 2479098 0 0 2479098 3294797 0 0 3294797 2479098 0 0 2479098 0 3294797 2479098 3287700 7097 844173 0 -1659872 15452793 0.05 0.05 0.05 1125 1125 562.5 10 0.50 16876000 16883000 17727000 3287700 0.2000 0.20 131526 2.25 378238 10386 90770 3902300 4003456 197191 4424609 -421153 799391 378238 939718 3287700 0 -818279 -0.31 00 33793379 4690446904 591 2092500 313 4143 0 46000 0 0 -364 -2475 -400 0 37500 904 898 0 1315.62 61.08 1375.18 0 4.4 0 0 197.34 720.45 2951.12 0 2945.09 2963.46 P5Y7M6D P6Y4M21D P6Y4M21D P9Y5M9D P1Y8M23D P1Y8M12D 0 0 0 0 0 0 129375 0 0 6614243 112500 16875 129375 0 0 5901743 0 0 0 -437500 0 0 0 0 -129375 1150000 0 0 20 0 0 4.49 20 0 0 4.77 0 0 0 2.25 0 0 0 0 20 2.25 0 1625911 6781007 393437 1232474 5156599 0 0 0 -1503 0 5.27 1.58 14.74 2.25 1.21 0 0 0 2739.75 0 14563539 86494 3422182 0 0 5000000 5000000 11091425 13908560 1232381 1545396 2500000 2500000 2777962 1111111 2.25 2.25 0.001 0.001 2.25 2.48 2600 6000000 2052257 0.10 0.10 8941000 8.89 8.89 46000 46000 P5Y P10Y 10 8479000 0.15 0.13 4929523 20 20 0 4172575 677778 200000 3294797 3156876 677778 0 2479098 3287700 200000 250000 200000 0.05 0.05 0.08 0.05 0.05 0.05 0.50 1275188 56000 27778 100000 61571 61941 123511 36 months 2012-02-15 2015-03-08 27611000 32190080 1858000 1882238 1735000 3051920 -2220000 -1202556 424000 19241 29408000 36270923 29408000 36270923 0 0 0 330000 -60457 -1758001 -75000 -75000 -277 230643 0 330000 438018 10392361 83637000 0.34 0.34 2032 132000 31000000 The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated. 7368000 15000000 7500000 7500000 The Board of Directors of the Company shall nominate a designee names by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock. 1000000 2000000 0 1981000 5000000 750000 20000000 7000000 80000 150000 0.1000 0.0200 250000000 2000000 182500000 9857596 1150000 -302284 -8790003 P13M 0 0 2797600 <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes warrant activity for the years ended December 31, 2012 and 2011:</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold; text-decoration: none;" colspan="2" nowrap="nowrap">Warrants</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-decoration: none;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted-<br />average<br />exercise price</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="font-size: 10pt;">Outstanding at January 1, 2011</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.24in; width: 58%; font-size: 10pt;">Assumed in Exchange Transaction</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 10%; font-size: 10pt;">393,437</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 10%; font-size: 10pt;">14.74</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="width: 2%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> <td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td> <td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Issued</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">1,232,474</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">2.25</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Exercised</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Expired</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; font-size: 10pt;">Outstanding at December 31, 2011</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">1,625,911</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">5.27</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Issued</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">5,156,599</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">1.21</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.24in; font-size: 10pt;">Exercised</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">--</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> <td style="text-align: right; font-size: 10pt;">&#160;</td> <td style="text-align: left; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt; padding-left: 0.24in; font-size: 10pt;">Expired</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(1,503</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">2,739.75</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> <td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; font-size: 10pt;">Outstanding at December 31, 2012</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">6,781,007</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.58</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">14,563,539</td> <td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> (1) The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of preferred stock was convertible into 8.89 shares of the Company's Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date. 0001001316tgtx:NationalHoldingsMember2012-04-30 695428 0.067 0001001316tgtx:TgBioMember2012-12-31 0.429 P5Y 0 0 2479098 3294797 0 0 5333 4732 0001001316tgtx:RestrictedPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2011-01-012011-12-31 0001001316tgtx:RestrictedPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2012-01-012012-12-31 0001001316tgtx:RestrictedCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2012-01-012012-12-31 0001001316tgtx:RestrictedPreferredStockMember2011-01-012011-12-31 0001001316tgtx:RestrictedCommonStockMember2012-01-012012-12-31 86494 86494 188509 0001001316tgtx:RestrictedPreferredStockMember2012-01-012012-12-31 188509 3233674 3233674 <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"><b>CORRECTION OF AN IMMATERIAL ERROR</b></p> <div style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;">&#160;</div> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;&#160;The Company has identified certain immaterial errors in its previously issued consolidated financial statements for the year ended December 31, 2011. In connection with the Exchange Transaction (see description above), a valuation using the guidance in the accounting literature for business combinations was performed to determine the fair value of the assets acquired and liabilities assumed. The Company has determined that certain methodologies and assumptions utilized in this valuation were incorrect. As a result of this, the Company has recorded an adjustment to previously reported in-process research and development, goodwill, and notes payable, less current portion, at fair value, at December 31, 2011 as follows:</p> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td> <td>In-process research and development decreased from $5,441,839 to $3,902,300</td> </tr> </table> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td> <td>Goodwill increased from $629,752 to $799,391</td> </tr> </table> <table style="font: 10pt/normal times new roman, times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.5in;"></td> <td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td> <td>Notes payable, less current portion, at fair value decreased from $4,664,697 to $3,294,797</td> </tr> </table> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;"></p> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;The net effect of this adjustment is a decrease to total assets and liabilities, as previously reported, of $1,369,900.</p> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p> <p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;The adjustment was recorded as of December 31, 2011 and has no effect on the statement of operations or statement of equity for any period. The Company assessed the impact of this adjustment under the provisions of SEC Staff Accounting Bulletin Nos. 99 and 108 and determined the impact of the errors to be immaterial to the financial statements. The accompanying consolidated balance sheet as of December 31, 2011 reflects the corrections of the aforementioned immaterial errors.</p> less than three months 0001001316us-gaap:SeriesAPreferredStockMember2011-12-29 8.89 0001001316tgtx:ImpairmentChargeMember2011-12-012012-12-31 1104700 0 8.89 7500000 00010013162012-04-012012-04-30 P5Y 0 1719828 less than $1,000 P2Y9M18D 46000 2580000 0001001316us-gaap:RestrictedStockMember2012-12-31 13526 13526 2.25 231580 295933 82305 one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate 0.95 132000 281250 P5Y P3M 500